Companies › Ascentage Pharma Group
8 active drug programs in 40 registered trials: 23 Phase 1, 9 Phase 2, 8 Phase 3; Oncology, Hematology, Other, Immunology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Apg-2575 Apoptosis regulator Bcl-2 inhibitor | BCL2 | Phase 3 | CLL/SLL; Acute Myeloid Leukemia; Higher-risk Myelodysplastic Syndrome; Chronic Lymphocytic Leukemia … | Dec 2026 |
| Olverembatinib Bcr/Abl fusion protein inhibitor | ABL1, BCR | Phase 3 | GIST; Chronic Myeloid Leukemia; Ph+ ALL; Pharmacokinetic … | Mar 2027 |
| APG-115 MDM2 inhibitor | MDM2 | Phase 2 | T-Prolymphocytic Leukemia; Unresectable or Metastatic Melanoma or Advanced Solid Tumors; Liposarcoma; Neuroblastoma … | Jan 2027 |
| APG-2449 Multi-targeted tyrosine kinase inhibitor; FAK, ALK, and ROS1 inhibitor | FAK, ALK, ROS1 | Phase 1 | Platinum-resistant Recurrent Ovarian Cancer; Advanced Solid Cancer | May 2027 |
| APG-5918 HIF-PHD inhibitor | PHD1, PHD2, PHD3 | Phase 1 | Anemia | Dec 2027 |
| APG-3288 Dual BCL-2 and MCL-1 inhibitor | BCL2, MCL1, BCL-XL | Phase 1 | Relapsed/Refractory Hematological Malignancies | Dec 2029 |
| APG-1252 BCL-2 family protein inhibitor | BCL2, BCL2L1, BCL2L2, MCL1 | Phase 1 | EGFR Positive Non-small Cell Lung Cancer | – |
| Osimertinib Mesylate (AZD9291) Epidermal growth factor receptor erbB1 inhibitor | EGFR | Phase 1 | EGFR Positive Non-small Cell Lung Cancer | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04494503 | Apg-2575 | Phase 1 | Chronic Lymphocytic Leukemia | Oncology | Oct 2024 |
| NCT04001777 | APG-1252 | Phase 1 | EGFR Positive Non-small Cell Lung Cancer | Oncology | Dec 2025 |
| NCT04001777 | Osimertinib Mesylate (AZD9291) | Phase 1 | EGFR Positive Non-small Cell Lung Cancer | Oncology | Dec 2025 |
| NCT03611868 | APG-115 | Phase 1 | Unresectable or Metastatic Melanoma or Advanced Solid Tumors | Oncology | Dec 2025 |
| NCT07282093 | Olverembatinib | Phase 1 | Pharmacokinetic | Other | Jun 2026 |
| NCT06757855 | Olverembatinib | Phase 1 | CML,Blast Phase | Oncology | Dec 2026 |
| NCT05147467 | Apg-2575 | Phase 2 | Chronic Lymphocytic Leukemia | Oncology | Dec 2026 |
| NCT06182969 | Apg-2575 | Phase 1 | SLE | Immunology | Dec 2026 |
| NCT05495035 | Olverembatinib | Phase 1 | Lymphoblastic Leukemia, Acute, Childhood | Oncology | Dec 2026 |
| NCT06104566 | Apg-2575 | Phase 3 | CLL/SLL | Oncology | Dec 2026 |
| NCT03913949 | Apg-2575 | Phase 1 | Chronic Lymphocytic Leukemia | Oncology | Dec 2026 |
| NCT05495035 | Apg-2575 | Phase 1 | Lymphoblastic Leukemia, Acute, Childhood | Oncology | Dec 2026 |
| NCT06401603 | Olverembatinib | Phase 1 | Advanced Chronic Myeloid Leukemia | Oncology | Jan 2027 |
| NCT04785196 | APG-115 | Phase 1 | Liposarcoma | Oncology | Jan 2027 |
| NCT03781986 | APG-115 | Phase 1 | Malignant Salivary Gland Cancer | Oncology | Jan 2027 |
| NCT06817720 | Olverembatinib | Phase 2 | Chronic Myeloid Leukemia | Oncology | Mar 2027 |
| NCT06640361 | Olverembatinib | Phase 3 | GIST | Oncology | Mar 2027 |
| NCT06687070 | APG-2449 | Phase 1 | Platinum-resistant Recurrent Ovarian Cancer | Oncology | May 2027 |
| NCT04496349 | Apg-2575 | Phase 2 | T-Prolymphocytic Leukemia | Oncology | May 2027 |
| NCT04496349 | APG-115 | Phase 2 | T-Prolymphocytic Leukemia | Oncology | May 2027 |
| NCT05701306 | Apg-2575 | Phase 1 | Neuroblastoma | Oncology | Jun 2027 |
| NCT05701306 | APG-115 | Phase 1 | Neuroblastoma | Oncology | Jun 2027 |
| NCT06423911 | Olverembatinib | Phase 3 | Chronic Myeloid Leukemia | Oncology | Jun 2027 |
| NCT04215809 | Apg-2575 | Phase 1 | CLL/SLL | Oncology | Jun 2027 |
| NCT06319456 | Apg-2575 | Phase 3 | CLL/SLL | Oncology | Aug 2027 |
| NCT05521204 | Olverembatinib | Phase 2 | Myeloproliferative Neoplasm | Oncology | Aug 2027 |
| NCT03594422 | Olverembatinib | Phase 1 | Gastrointestinal Stromal Tumor (GIST) | Oncology | Dec 2027 |
| NCT03917043 | APG-2449 | Phase 1 | Advanced Solid Cancer | Oncology | Dec 2027 |
| NCT06754267 | Olverembatinib | Phase 2 | Precursor B-Cell Acute Lymphoblastic Leukemia | Oncology | Dec 2027 |
| NCT06051409 | Olverembatinib | Phase 3 | Ph+ ALL | Oncology | Dec 2027 |
| NCT05773586 | APG-5918 | Phase 1 | Anemia | Hematology | Dec 2027 |
| NCT06220487 | Olverembatinib | Phase 2 | Acute Lymphoblastic Leukemia | Oncology | Jan 2028 |
| NCT06389292 | Apg-2575 | Phase 3 | Acute Myeloid Leukemia | Oncology | May 2028 |
| NCT07272499 | Apg-2575 | Phase 2 | Mantle Cell Lymphoma (MCL) | Oncology | Sep 2028 |
| NCT04501120 | Apg-2575 | Phase 1 | Relapsed/Refractory Acute Myeloid Leukaemia | Oncology | Sep 2028 |
| NCT07255963 | Apg-2575 | Phase 2 | DLBCL - Diffuse Large B Cell Lymphoma | Oncology | Sep 2028 |
| NCT06641414 | Apg-2575 | Phase 3 | Higher-risk Myelodysplastic Syndrome | Hematology | Jun 2029 |
| NCT07152041 | Olverembatinib | Phase 3 | Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+) | Oncology | Dec 2029 |
| NCT07424833 | APG-3288 | Phase 1 | Relapsed/Refractory Hematological Malignancies | Oncology | Dec 2029 |
| NCT04260022 | Olverembatinib | Phase 1 | Leukemia, Myeloid, Chronic | Oncology | Dec 2029 |
Cash of 893m CNY on 2024-12-31; operating cash outflow about 111m CNY a year; runway about 96 months at that burn, to Jan 2033; 6 of 6 coming phase 2-3 readouts fall inside that runway
Hutchmed Nuvation Bio Cogent Biosciences Corvus Pharmaceuticals Taiho Pharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.